Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Stoke Therapeutics (NASDAQ:STOK) to a strong-buy rating in a report issued on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th. Chardan Capital reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. Canaccord Genuity Group boosted their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Weiss Ratings downgraded Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, Wedbush raised their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Stoke Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Stoke Therapeutics Trading Down 6.1%

NASDAQ STOK opened at $29.46 on Monday. Stoke Therapeutics has a 1-year low of $11.66 and a 1-year high of $40.22. The firm’s fifty day simple moving average is $30.98 and its 200-day simple moving average is $32.33. The company has a market capitalization of $1.83 billion, a PE ratio of -10.48 and a beta of 1.17.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. The firm had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.48 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. As a group, analysts predict that Stoke Therapeutics will post -3.22 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 1,795 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the sale, the insider directly owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. The trade was a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total value of $43,637.15. Following the completion of the sale, the general counsel owned 18,086 shares in the company, valued at approximately $541,675.70. This represents a 7.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.60% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new stake in shares of Stoke Therapeutics in the 4th quarter worth about $26,000. KBC Group NV acquired a new stake in shares of Stoke Therapeutics during the first quarter worth approximately $36,000. Harbour Investments Inc. raised its stake in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after acquiring an additional 898 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.